Want to see HLN full AI Analyst Report?
HLN Stock Chart & Stats
$10.17
$0.16(1.64%)
At close: 4:00 PM EDT
$10.17
$0.16(1.64%)
Day’s Range― - ―
52-Week Range$8.65 - $11.28
Previous Close$9.94
Volume22.57M
Average Volume (3M)9.92M
Market Cap
$43.87B
Enterprise Value$51.55K
Total Cash (Recent Filing)$821.01M
Total Debt (Recent Filing)$8.20B
Price to Earnings (P/E)20.2
Beta0.13
Next Earnings
Mar 04, 2027EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend Yield1.25%
Share Statistics
EPS (TTM)0.36
Shares Outstanding4,398,267,000
10 Day Avg. Volume8,848,432
30 Day Avg. Volume9,922,989
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.70Price Target Upside15.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.57
Revenue Forecast (FY)$15.35B
Bulls Say, Bears Say
Bulls Say
Profitability And Cash GenerationStrong earnings-to-cash conversion supports internal funding, debt reduction and shareholder returns. The sharp 2025 free-cash-flow improvement, alongside expanding margins, indicates better operating efficiency, although cash generation remains somewhat variable.
Branded Oral Health GrowthOral care provides recurring, high-frequency purchases and benefits from strong global brands and retail penetration. Sustained growth across Sensodyne, Parodontax and Denture Care supports Haleon’s category leadership and recurring demand.
Margin Expansion And ProductivitySupply-chain efficiencies and operating-model savings can provide durable support to margins beyond pricing benefits. Management’s sizable savings program should improve earnings resilience and create capacity for continued investment in brands, innovation and digital channels.
Bears Say
Meaningful Debt LoadAlthough leverage has improved, the absolute debt burden remains material for a company facing soft top-line growth. Debt limits financial flexibility, increases sensitivity to funding costs and may constrain acquisitions or reinvestment if operating conditions weaken.
Recent Top-Line WeaknessWeak recent reported revenue tempers the benefit of margin expansion and raises the need for sustained volume, innovation and market-share gains. If growth remains muted, productivity savings may increasingly be required to support earnings progression.
Respiratory And Regional ExposureWeakness in respiratory products and several regions exposes Haleon to uneven category and geographic performance. The company’s large positions in some affected markets can amplify declines, making growth more dependent on oral care, North America and emerging markets.
Haleon PLC Sponsored ADR News
HLN FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was $8.65 and its highest was $11.28 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is $43.87B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Mar 04, 2027 which is in 181 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Jul 30, 2026. The company reported $0.116 earnings per share for the quarter, missing the consensus estimate of $0.129 by -$0.013.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR pays a Semiannually dividend of $0.064 which represents an annual dividend yield of 1.25%. See more information on Haleon PLC Sponsored ADR dividends here
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 0.28.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,398,267,000 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of $0.116 in its last earnings report, missing expectations of $0.129. Following the earnings report the stock price went down -1.654%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.70 (15.04% Upside)
$11.70 (15.04% Upside)
Blogger Sentiment
Neutral
HLN Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.47%
12-Months-Change
Fundamentals
Return on Equity
1.25%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Haleon PLC Sponsored ADR
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
HLN Company Deck
HLN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.View all HLN earnings summariesHLN Stock 12 Month Forecast
Average Price Target
$11.70
▲(15.04% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
4.70% Mutual Funds
5.94% Other Institutional Investors
89.18% Public Companies and
Individual Investors